Lowest Price Guaranteed
Pages
481
Last Updated
April 2026
View Count
16775
The field of oral proteins / peptides has enormous opportunities. I believe the field will continue to grow at a rapid pace considering the healthy clinical pipeline of oral proteins / peptides.
-Chief Executive Officer, US based small-sized developer
The global oral proteins and peptides market, valued at USD 2.47 billion in 2025, is projected to reach USD 3.26 billion in 2026 and USD 8.42 billion by 2035, with a 17.1% CAGR during the forecast period 2026 to 2035. Oral proteins and peptides refer to biologically active molecules that are administered orally, typically in the form of capsules, tablets, or liquids, for the treatment of various diseases including gastric, metabolic disorders, chronic disease, and others.
 |
To learn more about this report, request a free sample copy
Please click on the thumbnail images to expand and view the details.
 |
 |
 |
 |
 |
 |
 |
 |
 |
Oral proteins and peptides refer to biologically active molecules that are administered orally, typically in the form of capsules, tablets, or liquids, for the treatment of various diseases including gastric, metabolic disorders, chronic disease, and others. Historically, administering proteins and peptides has been a significant challenge, as these delicate molecules often struggle to survive the harsh gastrointestinal environment and reach their intended targets. However, the latest advancements in drug delivery technology have paved the way for a new era of orally administered protein and peptide therapies. The FDA's approval of several innovative oral protein and peptide drugs has been a testament to the industry's commitment to overcoming these obstacles.
These innovative therapies have the potential to revolutionize the treatment of a wide range of conditions, from diabetes to hormone deficiencies, while offering patients a more convenient and comfortable alternative to injectable or intravenous administration. Consequently, the oral protein and peptide market represents a rapidly evolving landscape in the pharmaceutical industry, mainly driven by the promise of enhanced bioavailability, improved patient compliance, and the potential to address a myriad of unmet medical needs.
As the field continues to witness technological advancements, the market potential for these innovative therapies has become increasingly compelling. For example, the FDA has approved several oral protein and peptides based-therapies and the most recently approved oral protein and peptide therapy is Mycapssa® (octreotide capsules) which is used for long-term maintenance treatment in acromegaly patients who have responded to and tolerated injectable. Likewise, in order to develop innovative therapies with growing advancement, stakeholders in the oral proteins and peptides market have boosted research efforts for novel biological targets to reinforce their pipelines.
The market research report presents an in-depth analysis of the various companies that are engaged in the global market of oral proteins and peptides, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2032 | |
| Market Size 2026 | USD 3.26 Billion | |
| Market Size 2032 | USD 8.42 Billion | |
| CAGR (Till 2032) | 17.1% | |
| Type of Target Disease Indication |
|
|
| Type of Molecule |
|
|
| Type of Biological Target |
|
|
| Type of Mechanism of Action |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled in the oral proteins and peptides market |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this oral proteins and peptides market report was to estimate the current market size, opportunity, and future growth potential of the oral proteins and peptides, over the forecast period. Based on multiple parameters, likely adoption trends, and through primary validations, we have provided an informed estimate of the market evolution during the forecast period, till 2032. The market report also features the likely distribution of the current and forecasted opportunity within the oral proteins and peptides market across various segments, such as type of target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type ii diabetes), molecule (protein and peptide), technology platforms, biological target (GC-C, insulin receptor, oxalate and others), mechanism of action (receptor stimulation, substrate degradation and others), and key geographical regions (North America, Europe and Asia Pacific, Latin America, Middle East, North Africa and rest of the world).
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified. The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market research report includes detailed transcripts of discussions held with
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
The global oral proteins and peptides market is categorized across a diverse range of target disease indications such as Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes. As per our research, type II diabetes is anticipated to be a leading segment with the largest 46.9% of the oral proteins and peptides market shares by 2032. This can be ascribed to the mounting diabetes specifically, type II diabetes cases worldwide which is a major factor to boost the demand for effective and convenient treatment. Therefore, the demand for oral alternatives to injectable insulin and other peptides will likely increase and type II diabetes will grow at a higher CAGR of 83.01% till 2032.
Based on the type of molecules, the oral proteins and peptides market is segmented into Protein and Peptide. According to our projection, peptide molecules will likely dominate the segment until 2032 with an overall share of 69.27%. Protein molecules are expected to drive the market at a higher CAGR of 92% over this forecast period. Owing to protein molecules benefits in overcoming significant challenges, such as ensuring stability in the acidic environment of the stomach and achieving sufficient absorption in the intestines making it a strong molecule for oral protein and peptide therapeutics.
This segment underscores the distribution of the oral proteins and peptides market based on a wide range of biological targets such as GC-C, Insulin Receptor, Oxalate, and Others. According to this projection, other targets will dominate the biological targets segment with 38.58% by 2032 in terms of revenue. It will also likely grow at a higher CAGR of 37.83% during the forecast period till 2032.
Based on the mechanism of action, the market is categorized into Receptor Stimulation, Substrate Degradation, and Others. In terms of revenue, receptor stimulation is likely to acquire 56.73% by 2032. Due to its remarkable impact on chronic diseases and the successful introduction of essential oral therapies targeting receptors, the segment will likely accelerate the market growth throughout the forecast. Other mechanisms of action are projected to drive the market at a higher CAGR of 39.21% over this projection timeframe.
This segment highlights the distribution of the oral proteins and peptides market across various geographies, such as North America, Europe, Asia-Pacific Latin America, Middle East and North Africa. As per our projections, in terms of revenue, North America captures the largest market share and is likely to lead the global market for oral proteins and peptides primarily, due to the growing incidence of chronic diseases and higher demand for oral drugs particularly, among geriatric and pediatric patient populations. Additionally, Europe is emerging as the second-largest market for oral proteins and peptides and is anticipated to propel the market at a higher CAGR till 2032.
The “Oral Proteins and Peptides Market: Industry Trends and Global Forecasts, till 2032” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in development of oral protein and peptides. The market report highlights the efforts of several manufacturers of oral protein and peptide therapeutics and technology platform providers in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market size, competitive landscape, and geographical regions in the oral protein and peptides market report are briefly discussed below.
Currently, multiple drug developers are present in the market and various claim to have strong pipelines of drugs, aiming at addressing disorders with high unmet needs. In this context, around 100 scientists, key industry players, affiliated medical and commercial organizations are at the forefront of research in oral protein and peptide therapeutics. The drug developers in this area have more than 40 technology platforms available for the development of oral proteins and peptides, based on multiple approach such as permeation enhancement, encapsulation and more.
In addition to this, leading drug developers are actively exploring various commercialization strategies suitable for different stages of the product launch cycle which aid them in effectively monetizing their proprietary offerings, and is expected to boost the oral proteins and peptides market potential over the forecast period.
The growth of the oral proteins and peptides market is mainly driven by the rising prevalence of chronic diseases such as diabetes, chronic idiopathic constipation, and others. These chronic diseases require daily dose of medicine, sometime multiple dose in a day. Owing to the large size of proteins, they are mainly injectable drugs. This impacts the medication adherence rates. Oral drugs offer patient friendly options. Along with this, the continuous research & development activities for novel effective therapies coupled with increasing regulatory approvals for oral protein and peptide drugs are attributed to encourage further development in the market.
In recent years, the oral proteins and peptides market has been growing exponentially driven by emerging trends and growing demand for non-invasive therapies. One of the latest trends in the market is the ongoing advancements in drug discovery technology. With regard to this, the increasing utilization of nanotechnology in drug discovery is generating immense opportunities for market players to develop therapies that enhance the stability, absorption, and bioavailability of oral proteins and peptides. This technology aids in protecting the therapeutic molecules from degradation in the gastrointestinal tract.
With respect to this, over 40 advanced technology platforms are being leveraged by industry players for the development of oral proteins and peptides. US headquartered, Biora Therapeutics announced its plans to present the results from preclinical trials of the latest techology, BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit to be held in June 2024. These advanced technologies have increased the potential of oral protein and peptide therapies in targeted delivery, offer convenient alternatives to injections, and expand their use to treat various medical conditions. Owing to this, stakeholders are actively following innovation in this field. As a result, around 50% of the development programs are in their early stages.
In respect of regional insights, the global market for oral proteins and peptides is projected to be dominated by North America. Oral proteins and peptide developers in the region substantially stimulate the growth of the oral proteins and peptides market. In addition, the high prevalence of chronic diseases with an increasing geriatric population and rising preference for oral drugs is attributed to the market demand. Also, its well-established pharmaceutical industry, emerging start-ups, and their expanded R&D efforts in developing oral protein and peptide therapies are driving the market growth.
It is worth highlighting that approximately 43% of organizations are pharma companies headquartered in North America. Along with the key industry players, numerous medical research organizations are propelling the market by continuously publishing scientific articles which can be attributed to the region’s dominance in the global marketplace. For instance, in 2024, Johnson & Johnson presented phase II trial results for JNJ-2113, the first oral peptide under development for treatment of moderate-to-severe plaque psoriasis.
Examples of key technology platforms used for the production of oral proteins and oral peptides (which have also been profiled in this market report; the complete list of technology platforms is available in the full report) include Axcess™ Oral Drug Delivery Technology, Eligen™ Technology, Entera Technology, NTRA Oral Delivery Technology, Peptelligence® Technology, Protein Oral Delivery (POD™) Technology, Transient Permeability Enhancer (TPE®) Technology and Uroguanylin Analogue Technology. This market report includes an easily searchable excel database of all the oral proteins, oral peptides, technology platforms and companies involved in oral proteins and peptides market, worldwide.
In the past few years, the market for oral proteins and peptides market has been blooming. Several ongoing innovations and developments are projected to boost market potential. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our oral proteins and peptides market analysis.